Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer
Taylor J, Kamat A, O'Donnell M, Annapureddy D, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y. Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer. BJU International 2024 PMID: 39183466, DOI: 10.1111/bju.16509.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerBladder-sparing therapyUpfront RCRadical cystectomyCohort of patientsBladder cancerBCG-unresponsive NMIBCRetrospective cohort of patientsProgression to MIBCUpfront radical cystectomyCancer-specific survivalInstitutional review board approvalMetastasis-free survivalFood and Drug Administration criteriaRate of recurrenceReview board approvalLong-term outcomesStatistically significant differenceNodal diseaseRe-resectionSystemic immunotherapyIntravesical chemotherapyOncological outcomesOverall survivalOncological riskBladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection
Li R, Hensley P, Gupta S, Al-Ahmadie H, Babjuk M, Black P, Brausi M, Bree K, Fernández M, Guo C, Horowitz A, Lamm D, Lerner S, Lotan Y, Mariappan P, McConkey D, Mertens L, Mir C, Ross J, O'Donnell M, Palou J, Pohar K, Steinberg G, Soloway M, Spiess P, Svatek R, Tan W, Taoka R, Buckley R, Kamat A. Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. European Urology 2024 PMID: 39183090, DOI: 10.1016/j.eururo.2024.08.001.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder-sparing treatmentCarcinoma in situNadofaragene firadenovecRadical cystectomyBladder cancerOptimal selection of patientsAbsence of randomized trialsBladder-sparing therapySingle-agent chemotherapyBladder cancer groupSelection of patientsDevelopment of agentsPatient selectionSystemic toxicityCancer groupUnapproved agentsClinical trial participationPatient characteristicsRandomized trialsMitomycin CTumor attributesConsensus recommendationsCancer expertsMultiomics profiling of urothelial carcinoma in situ reveals CIS-specific gene signature and immune characteristics
Anurag M, Strandgaard T, Kim S, Dou Y, Comperat E, Al-Ahmadie H, Inman B, Taber A, Nordentoft I, Jensen J, Dyrskjøt L, Lerner S. Multiomics profiling of urothelial carcinoma in situ reveals CIS-specific gene signature and immune characteristics. IScience 2024, 27: 109179. PMID: 38439961, PMCID: PMC10910238, DOI: 10.1016/j.isci.2024.109179.Peer-Reviewed Original ResearchCarcinoma in situCarcinoma in situ lesionsUrothelial carcinoma in situPapillary tumorsAggressive phenotypeAssociated with carcinoma in situNon-muscle-invasive bladder cancerCarcinoma in situ samplesPD-1-positive cellsImmune marker expressionBladder cancerImmunological landscapeMarker expressionTumorGene signatureMutational heterogeneityImmune characteristicsMutated genesExpression signaturesTargeting mTORHigher expressionTime pointsMutation analysisMultiomic profilingLesions